Artificial intelligence continues to redefine medicine, as AI has successfully created and delivered the first dose of a groundbreaking drug. Developed by Insilico Medicine, the drug INS018_055 is an anti-fibrotic small molecule inhibitor designed with generative AI. After passing rigorous trials, the drug is now being tested for idiopathic pulmonary fibrosis, a lung disease characterized by scarring. This remarkable achievement showcases the immense potential of AI in the field of medicine. Stay tuned for more updates on this groundbreaking development.

Patients Receive First-Ever Drug Created By Generative AI